GeneDx Holdings Corp (WGS) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic ... [Yahoo! Finance]
GeneDx Holdings Corp. - Class A (WGS)
Company Research
Source: Yahoo! Finance
3 min read In This Article WGSWW Revenue: Fourth-quarter 2024 revenue reached $95.3 million. Exome and Genome Revenue: Grew 101% year-over-year and 31% sequentially, contributing $78.8 million. Gross Margin: Adjusted gross margin expanded to 70% in the fourth quarter, up from 56% a year ago. Net Income: Adjusted net income for the fourth quarter was $16.8 million. Cash and Equivalents: Totaled $142.2 million as of December 31, 2024. Cash Flow: Generated $12.4 million in cash from ordinary operations in the fourth quarter. Guidance for 2025: Expected revenue between $350 million to $360 million, with at least 30% growth in Exome and Genome volume and revenue. Reimbursement Rate: Average reimbursement rate for exome and genome tests was approximately $3,500 in the fourth quarter. Warning! GuruFocus has detected 4 Warning Sign with WGS. Release Date: February 18, 2025 For the complete transcript of the earnings call, please refer to the full earnings call trans
Show less
Read more
Impact Snapshot
Event Time:
WGS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
WGS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
WGS alerts
High impacting GeneDx Holdings Corp. - Class A news events
Weekly update
A roundup of the hottest topics
WGS
News
- GeneDx (NASDAQ:WGS) was given a new $155.00 price target on by analysts at Wells Fargo & Company.MarketBeat
- JAMA (Journal of the American Medical Association) Recognizes GUARDIAN Newborn Genomic Screening Study Among Its Research of the YearBusiness Wire
- GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Be 40% Below Their Intrinsic Value Estimate [Yahoo! Finance]Yahoo! Finance
- GeneDx (NASDAQ:WGS) had its price target raised by analysts at BTIG Research from $165.00 to $200.00. They now have a "buy" rating on the stock.MarketBeat
- HALPER SADEH LLC ENCOURAGES GENEDX HOLDINGS CORP. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
WGS
Earnings
- 10/28/25 - Beat
WGS
Sec Filings
- 12/18/25 - Form 4
- 12/18/25 - Form 4
- 12/11/25 - Form 4
- WGS's page on the SEC website